Shrim Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -34.36%
- Profit Growth -196.05%
- Ebitda -170.97%
- Net Worth -10.12%
- Total Assets -9.90%
About Shrim Pharma
Shrim Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 March 2012 and has a history of 12 years and ten months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Vikas Modi, Damyanti Modi, and Shilpa Shah serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U52100MH2012PTC228795
-
Company No.
228795
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Mar 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Shrim Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Modi
|
Director | 03-Oct-2016 | Current |
|
Damyanti Modi
|
Director | 28-Mar-2012 | Current |
|
Shilpa Shah
|
Director | 28-Mar-2012 | Current |
Financial Performance of Shrim Pharma.
Shrim Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 34.36% decrease. The company also saw a substantial fall in profitability, with a 196.05% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shrim Pharma?
In 2021, Shrim Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Ashtavinayak Medicals LlpVikas Modi is a mutual person
-
Nephonc Biotech Private Limited
Vikas Modi is a mutual person
-
Goldi Hotels Private Limited
Damyanti Modi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shrim Pharma?
Unlock and access historical data on people associated with Shrim Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shrim Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shrim Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
